Buchumschlag

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Danny Con
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
von: Lesley A. Patmore, et al.
Veröffentlicht: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
von: Kaitlyn Carlson, et al.
Veröffentlicht: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
von: Jia‐Ling Wu, et al.
Veröffentlicht: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Shinya Yokoyama, et al.
Veröffentlicht: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
von: Elisa Pinto, et al.
Veröffentlicht: (2026)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
von: Zhejin Shi, et al.
Veröffentlicht: (2026)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2025)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
von: Vincent Haghnejad, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
von: Thomas Hoang, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
von: Kanghee Park, et al.
Veröffentlicht: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
von: Jonggi Choi
Veröffentlicht: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
von: Daniel Q. Huang, et al.
Veröffentlicht: (2026)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
von: Thomas Hunold, et al.
Veröffentlicht: (2025)

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma
von: Ashwini Arvind, et al.
Veröffentlicht: (2025)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
von: Gustavo Ayares, et al.
Veröffentlicht: (2024)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Gian Paolo Caviglia, et al.
Veröffentlicht: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
von: Miriam T. Levy
Veröffentlicht: (2026)

Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting
von: Toni Herta, et al.
Veröffentlicht: (2024)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
von: Tyng‐Yuan Jang, et al.
Veröffentlicht: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
von: Paul Y. Kwo, et al.
Veröffentlicht: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
von: Ahmed Helmy
Veröffentlicht: (2025)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
von: Yuxin Chen, et al.
Veröffentlicht: (2024)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
von: Marco Sanduzzi‐Zamparelli, et al.
Veröffentlicht: (2026)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
von: Kunhee Kim, et al.
Veröffentlicht: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
von: Peng Zhang, et al.
Veröffentlicht: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
von: Seogsong Jeong, et al.
Veröffentlicht: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
von: Mohammad Saeid Rezaee‐Zavareh, et al.
Veröffentlicht: (2026)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
von: Soon Sun Kim, et al.
Veröffentlicht: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
von: Gamal Shiha, et al.
Veröffentlicht: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
von: Yanxue Lin, et al.
Veröffentlicht: (2025)

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
von: Simone Chin, et al.
Veröffentlicht: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
von: Johnny Yau‐Cheung Chang, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
von: J. Ventre, et al.
Veröffentlicht: (2025)